Advances in Cancer Immunotherapy: Annual Update

This is a Hybrid Event. Registrants will be able to choose if they would like to attend in-person or virtually.

Cancer treatment has evolved significantly over the past decade from a treatment paradigm anchored on surgery, chemotherapy, and radiotherapy, to one embracing molecularly-targeted therapies disrupting tumor-specific signaling pathways, as well as new approaches to mobilize the immune system. For clinicians trying to keep current with advancing immuno-oncology principles and research, the pace of these developments has brought new challenges. Recognizing these challenges, this course will provide a comprehensive clinical review of the advances taking place in the immuno-oncology field.

Target audience

This activity is intended for physicians, nurses, physician assistants, and other members of the healthcare team.

Learning objectives

Upon completion of this activity, participants will be able to:

1. Evaluate cancer immunotherapy principles and strategies and how they influence current treatment approaches.
2. Identify the emerging role of personalized cancer vaccination and other immunotherapy combinations in patients with solid tumor and hematologic malignancies.
3. Define currently approved and emerging predictive biomarkers for cancer immunotherapy.
4. Recognize and implement management strategies for immune-mediated side effects in patients treated with immunotherapy agents.
5. Recognize the importance of establishing a multidisciplinary approach in the immunotherapy era.

For exhibit space, please contact ebrooks3@mgh.harvard.edu

Registration instructions

Cancellation Policy:
Registrations cancelled on or before April 17, 2023 will be refunded, less a $25 administrative fee. Registrations cancelled after April 17, 2023 will not be refunded.

Contact partnerscpd@partners.org if you require assistance in cancelling your online registration.

Accommodations:

A limited number of rooms have been reserved at The Westin Copley Place for the nights of April 30 and May 1 at nightly rate of $279. Hotel room rates are subject to applicable state and local taxes in effect at the time of check-out. To book your room, contact the hotel at (617) 262-9600. The reservation deadline is Friday, April 7, 2023.

Additional information

Massachusetts General Hospital Cancer Center & Mass General Brigham 

Faculty credentials

Course Directors

Justin Gainor, MD
Director, Center for Thoracic Cancers,
Director of Targeted Immunotherapy,
Massachusetts General Hospital Cancer Center;
Associate Professor of Medicine, Harvard Medical School

Krista Rubin, MS, FNP-BC
Nurse Practitioner, Center for Melanoma,
Massachusetts General Hospital Cancer Center 

Ryan Sullivan, MD
Physician Investigator, Cancer Center, Mass General Research Institute;
Assistant In Medicine, Hematology-Oncology, Massachusetts General Hospital;
Associate Professor of Medicine, Harvard Medical School

Faculty

Jeremy Abramson, MD
Director, Jon and Jo Ann Hagler Center for Lymphoma,
Massachusetts General Hospital Cancer Center;
Associate Professor of Medicine, Harvard Medical School

Hugh Auchincloss, MD
Thoracic Surgery,
Massachusetts General Hospital

Mark Awad, MD, PhD
Clinical Director, Thoracic Oncology Treatment Center,
Dana-Farber Cancer Institute;
Associate Professor of Medicine, Harvard Medical School

Steven Blum, MD
Instructor in Medicine,
Massachusetts General Hospital

Genevieve Boland, MD, PhD
Vice Chair of Research, Department of Surgery,
Director, Therapeutic Intralesional Program,
Surgical Director, Termeer Center for Targeted Therapies,
Massachusetts General Hospital

Jonathan H. Chen, MD, PhD
Instructor in Pathology,
Massachusetts General Hospital

Riley Fadden, MSN, RN, FNP-C 
Nurse Practitioner, Center for Melanoma,
Massachusetts General Hospital Cancer Center

Florian Fintelmann, MD
Radiologist, Thoracic Imaging and Intervention,
Head, Thoracic Imaging Percutaneous Thermal Ablation,
Massachusetts General Hospital;
Associate Professor, Harvard Medical School

Ruth Foreman, MD
Assistant Pathologist, Dermatopathology Service,
Massachusetts General Hospital;
Instructor, Harvard Medical School

Xin Gao, MD
Assistant in Medicine,
Massachusetts General Hospital Cancer Center;
Assistant Professor, Harvard Medical School

Rakesh Jain, PhD
Director, Steele Laboratory, Massachusetts General Hospital;
A. Werk Cook Professor of Radiation Oncology, Harvard Medical School

Howard Kaufman, MD
Assistant in Surgery, Surgery, Massachusetts General Hospital;
Lecturer in Surgery, Harvard Medical School

Florence (Katie) Keane, MD
Assistant Professor in Radiation Oncology,
Massachusetts General Hospital

Jason J. Luke, MD, FACP
Director of the Cancer Immunotherapeutics Center,
University of Pittsburgh

Mari Mino-Kenudson, MD
Director, Pulmonary Pathology,
Pathologist, Massachusetts General Hospital;
Professor of Pathology, Harvard Medical School

Patrick Ott, MD, PhD
Clinical Director, Melanoma Disease Center,
Director, Clinical Sciences, Center for Immuno-Oncology,
Dana-Farber Cancer Institute;
Associate Professor of Medicine, Harvard Medical School

Jong Chul Park, MD
Assistant Professor of Medicine,
Massachusetts General Hospital Cancer Center

Laura Petrillo, MD
Palliative Care Physician, Massachusetts General Hospital;
Assistant Professor of Medicine, Harvard Medical School

Arlene Sharpe, MD, PhD
Kolokotrones University Professor,
Chair, Department of Immunology,
Harvard Medical School

Alexandra-Chloe Villani, PhD
Director, Single-Cell Genomics Program,
Center for Immunology and Inflammatory Diseases,
Massachusetts General Hospital;
Assistant Professor of Medicine, Harvard Medical School;
Associate Scientist, Broad Institute of MIT and Harvard

Leyre Zubiri, MD, PhD
Immunotherapy Toxicity Fellow,
Severe Immunotherapy Complications Service,
Massachusetts General Hospital Cancer Center

Accreditation

In support of improving patient care, Mass General Brigham is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Credit Designation Statements

AMA PRA Category 1 Credits^TM
Mass General Brigham designates this live activity for a maximum of 10.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing
Mass General Brigham designates this activity for 10.25 ANCC contact hours. Nurses should only claim credit commensurate with the extent of their participation in the activity

Program

Monday, May 1, 2023 | 7:30am – 4:15pm

Tuesday, May 2, 2023 | 7:30am – 1:00pm